Track Silexion Therapeutics Ltd. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Silexion Therapeutics Ltd. SLXN Open Silexion Therapeutics Ltd. in new tab

0.2735 USD
EPS
-8.96
P/B
0.35
Beta
-0.29
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 18, 2026
EPS-8.96
Book Value0.83
Price to Book0.35
Debt/Equity78.22
% Insiders8.278%
Estimates
Forward P/E-0.45
Forward EPS-0.64

DCF Valuation

Tweak assumptions to recompute fair value for Silexion Therapeutics Ltd. (SLXN)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Silexion Therapeutics Ltd. Logo Silexion Therapeutics Ltd. Analysis (SLXN)

Israel Healthcare Official Website Stock

Is Silexion Therapeutics Ltd. a good investment? Silexion Therapeutics Ltd. (SLXN) is currently trading at 0.2735 USD.

Earnings Schedule: Silexion Therapeutics Ltd. is expected to release its next earnings report on Aug. 18, 2026. The market consensus estimate for Forward EPS is -0.64.

Investor FAQ

Does Silexion Therapeutics Ltd. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Silexion Therapeutics Ltd.?

Silexion Therapeutics Ltd. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 18, 2026. The company currently has a trailing EPS of -8.96.

Company Profile

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Exchange Ticker
NASDAQ SLXN

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
July 29, 2025 0.066667
July 29, 2025 0.070000
Nov. 29, 2024 0.110000
July 29, 2025 0.070000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion